A statistically significant higher concentration of IL-1β in the serum of patients with stage G3 ovarian cancer was demonstrated compared to the reference group (p<0.01), patients with stage G1 and G2 ovarian cancer (both p<0.05). This evidence concerns the gene IL1B and ovarian cancer.